Today Innovatus Capital Partners, LLC, an independent adviser and portfolio management firm with approximately $1.6 billion in assets under management, today announced that it has appointed Geoffrey Duyk, M.D., Ph.D., the founder and Managing Partner of Circularis LP, to its Life Sciences Advisory Board.
Dr. Duyk will serve as a member of the Innovatus Advisory Board. He is the founder and Managing Partner of Circularis LP, a group focused on supporting technology-enabled companies that advance the circular economy and promote sustainability as well as resource efficiency. Prior to Circularis, Dr. Duyk was the Managing Director and Partner of TPG Alternative & Renewable Technologies/TPG Biotechnology from 2004 to 2017. Prior to TPG, Dr. Duyk served on the Board of Directors and was President of Research and Development at Exelixis. Prior to Exelixis, he was one of the founding scientific staff at Millennium Pharmaceuticals and served as Vice President of Genomics. Prior to his tenure at Millennium, Dr. Duyk was an Assistant Professor at Harvard Medical School (HMS) in the Department of Genetics and an Assistant Investigator of the Howard Hughes Medical Institute. While at HMS, Dr. Duyk was a Co-Principal Investigator in the National Institutes of Health-funded Cooperative Human Linkage Center. Dr. Duyk holds a doctorate and medical degree from Case Western Reserve University. He completed his medical and fellowship training at the University of California, San Francisco. While at UCSF, Dr. Duyk was a fellow of the Lucille P. Markey Foundation and was awarded a post-doctoral fellowship from HHMI. In addition to Concentric, Dr. Duyk currently serves on the Board of Directors of Amyris (Nasdaq: AMRS), Concentric Agriculture and Regen Holdings. He is a former member of the Board of Directors and the executive committee for the American Society of Human Genetics and currently serves on its finance and investment committees. He is a trustee of Case Western Reserve University, where he chairs the finance committee and sits on the executive committee. He is a member of the Institute Board of Directors of the Moffitt Cancer Center, where he chairs the research and development committee. He has also served as a member of the Scientific Advisory Boards for Bayer Crop Sciences, Jackson Laboratories and Lawrence Berkeley National Laboratory, Department of Energy.
Headquartered in New York, Innovatus Capital Partners’ Life Sciences strategy (“Innovatus Life Sciences”) provides growth capital in the form of senior secured debt and equity to support life sciences and select technology companies, including medical devices, diagnostics, life science tools, biopharmaceuticals, specialty pharmaceuticals, healthcare IT and software. The Firm seeks to invest $20 to $50 million in public and private commercial-stage companies and offer flexible financing solutions to fund rapid commercial growth and development programs.
Innovatus’ Life Sciences Advisory Board, which is comprised of world-class thought leaders in the life sciences industry, provides counsel to the Firm on its investment strategy across life sciences sectors as the Firm seeks to partner with leading companies that address unmet medical needs, improve patient outcomes, reduce healthcare expenditures and create value for investors.
“We are pleased to welcome Geoff to Innovatus’ Life Sciences Advisory Board,” said David Schiff, Chief Executive Officer and Co-Founder of Innovatus. “With over three decades of experience in life sciences and related technology sectors, Geoff is uniquely positioned to advise us on life sciences investments while providing differentiated insights on our life sciences strategy. Geoff will undoubtedly be an immediate asset to the Advisory Board and we look forward to working closely with him.”
“We are delighted that Geoff has joined our Life Sciences Advisory Board,” said Claes Ekstrom, Managing Director at Innovatus. “Geoff has had an illustrious career in life sciences and has demonstrated success as a scientist, corporate executive and investor. We look forward to working with Geoff and getting his perspective on innovation that can help patients live longer, better and healthier lives.”
“Innovatus’ team is well-positioned to identify unique growth and investment opportunities across the life sciences spectrum, making them an ideal partner for emerging life sciences companies that need flexible and tailored loan structures, ” said Dr. Duyk. “I am honored to join the Advisory Board, and look forward to working alongside the firm’s dedicated life science team.”